Inhaled salmeterol and/or fluticasone alters structure/function in a murine model of allergic airways disease

Respiratory Research

Volumn 11, Issue , 2010, Pages

  Riesenfeld, Erik P ^a   Sullivan, Michael J ^a   Thompson Figueroa, John A ^a   Haverkamp, Hans C ^a   Lundblad, Lennart K ^a   Bates, Jason H T ^a   Irvin, Charles G ^a  

^a UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUTICASONE; METHACHOLINE; OVALBUMIN; SALMETEROL; ANDROSTANE DERIVATIVE; DRUG DERIVATIVE; FLUTICASONE, SALMETEROL DRUG COMBINATION; GLUCOCORTICOID; SALBUTAMOL;

ALLERGIC ASTHMA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL COUNT; CONTROLLED STUDY; FEMALE; LUNG CLEARANCE; LUNG COMPLIANCE; LUNG FUNCTION; LUNG LAVAGE; MICRO-COMPUTED TOMOGRAPHY; MOUSE; NONHUMAN; ANIMAL; ASTHMA; BAGG ALBINO MOUSE; DISEASE MODEL; DRUG COMBINATION; DRUG EFFECT; HUMAN; INHALATIONAL DRUG ADMINISTRATION; LUNG; PATHOLOGY; PATHOPHYSIOLOGY;

ADMINISTRATION, INHALATION; ALBUTEROL; ANDROSTADIENES; ANIMALS; ASTHMA; DISEASE MODELS, ANIMAL; DRUG COMBINATIONS; FEMALE; GLUCOCORTICOIDS; HUMANS; LUNG; MICE; MICE, INBRED BALB C;

EID: 77952517927     PISSN: 14659921     EISSN: 1465993X     Source Type: Journal    
DOI: 10.1186/1465-9921-11-22     Document Type: Article

References (47)

1. James AL, Wenzel S. Clinical relevance of airway remodelling in airway diseases. Eur Respir J 2007, 30:134-155. 10.1183/09031936.00146905, 17601971.
2. McParland BE, Macklem PT, Pare PD. Airway wall remodeling: friend or foe?. J Appl Physiol 2003, 95:426-434.
3. Kuyper LM, Pare PD, Hogg JC, Lambert RK, Ionescu D, Woods R, Bai TR. Characterization of airway plugging in fatal asthma. The American Journal of Medicine 2003, 115:6-11. 10.1016/S0002-9343(03)00241-9, 12867228.
4. Lundblad LKA, Thompson-Figueroa J, Allen GB, Rinaldi L, Norton RJ, Irvin CG, Bates JHT. Airway Hyperresponsiveness in Allergically Inflamed Mice: The Role of Airway Closure. Am J Respir Crit Care Med 2007, 175:768-774. 10.1164/rccm.200610-1410OC, 1899295, 17255559.
5. Wagers SS, Norton RJ, Rinaldi LM, Bates JHT, Sobel BE, Irvin CG. Extravascular fibrin, plasminogen activator, plasminogen activator inhibitors, and airway hyperresponsiveness. J Clin Invest 2004, 114:104-111. 437962, 15232617.
6. Wagers S, Lundblad LKA, Ekman M, Irvin CG, Bates JHT. The allergic mouse model of asthma: normal smooth muscle in an abnormal lung?. J Appl Physiol 2004, 96:2019-2027. 10.1152/japplphysiol.00924.2003, 14660507.
7. The National Asthma Education and Prevention Program (NAEPP): The Expert Panel Report 3 (EPR-3): Guidelines for the Diagnosis and Management of Asthma. 2007, 2007.
8. Woolcock A, Lundback B, Ringdal N, Jacques LA. Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids. Am J Respir Crit Care Med 1996, 153:1481-1488.
9. Anderson GP. Interactions between Corticosteroids and beta -Adrenergic Agonists in Asthma Disease Induction, Progression, and Exacerbation. Am J Respir Crit Care Med 2000, 161:188S-196.
10. Nelson HS, Weiss ST, Bleecker ER, Yancey SW, Dorinsky PM, . the SMART Study Group The Salmeterol Multicenter Asthma Research Trial: A Comparison of Usual Pharmacotherapy for Asthma or Usual Pharmacotherapy Plus Salmeterol. Chest 2006, 129:15-26. 10.1378/chest.129.1.15, 16424409, the SMART Study Group.
11. Salpeter SR, Buckley NS, Ormiston TM, Salpeter EE. Meta-Analysis: Effect of Long-Acting {beta}-Agonists on Severe Asthma Exacerbations and Asthma-Related Deaths. Ann Intern Med 2006, 144:904-912.
12. FDA Public Health Advisory Serevent Diskus (salmeterol xinafoate inhalation powder), Advair Diskus (fluticasone propionate & salmeterol inhalation powder), Foradil Aerolizer (formoterol fumarate inhalation powder). , http://www.fda.gov/Drugs/DrugSafety/PublicHealthAdvisories/ucm162678.htm
13. Papi A, Canonica GW, Maestrelli P, Paggiaro P, Olivieri D, Pozzi E, Crimi N, Vignola AM, Morelli P, Nicolini G, et al. Rescue Use of Beclomethasone and Albuterol in a Single Inhaler for Mild Asthma. N Engl J Med 2007, 356:2040-2052. 10.1056/NEJMoa063861, 17507703.
14. Barnes PJ. Scientific rationale for using a single inhaler for asthma control. Eur Respir J 2007, 29:587-595. 10.1183/09031936.00080306, 17329493.
15. Li X, Ward C, Thien F, Bish ROS, Bamford T, Bao X, Bailey M, Wilson JW, Haydn Walters E. An Antiinflammatory Effect of Salmeterol, a Long-acting beta 2 Agonist, Assessed in Airway Biopsies and Bronchoalveolar Lavage in Asthma. Am J Respir Crit Care Med 1999, 160:1493-1499.
16. Whelan C, Johnson M, Vardey C. Comparison of the anti-inflammatory properties of formoterol, salbutamol and salmeterol in guinea-pig skin and lung. Br J Pharmacol 1993, 110:613-618. 2175955, 7902175.
17. Howarth P. Effects of Beta2-Agonists on Airway Inflammation. Beta2-Agonists in Asthma Treatment 1997, 106:67-86. New York: Marcel Dekker Inc, Pauwels R, O'Byrne PM.
18. Takeda K, Hamelmann E, Joetham A, Shultz LD, Larsen GL, Irvin CG, Gelfand EW. Development of Eosinophilic Airway Inflammation and Airway Hyperresponsiveness in Mast Cell-deficient Mice. J Exp Med 1997, 186:449-454. 10.1084/jem.186.3.449, 2198995, 9236197.
19. Bates JHT, Wagers SS, Norton RJ, Rinaldi LM, Irvin CG. Exaggerated airway narrowing in mice treated with intratracheal cationic protein. J Appl Physiol 2006, 100:500-506. 10.1152/japplphysiol.01013.2005, 16239609.
20. Hantos Z, Daroczy B, Suki B, Nagy S, Fredberg JJ. Input impedance and peripheral inhomogeneity of dog lungs. J Appl Physiol 1992, 72:168-178. 10.1063/1.352153, 1537711.
21. Bates JHT, Cojocaru A, Haverkamp HC, Rinaldi LM, Irvin CG. The Synergistic Interactions of Allergic Lung Inflammation and Intratracheal Cationic Protein. Am J Respir Crit Care Med 2008, 177:261-268. 10.1164/rccm.200706-832OC, 2218848, 17962637.
22. Ito S, Ingenito EP, Arold SP, Parameswaran H, Tgavalekos NT, Lutchen KR, Suki B. Tissue heterogeneity in the mouse lung: effects of elastase treatment. J Appl Physiol 2004, 97:204-212. 10.1152/japplphysiol.01246.2003, 15020580.
23. Poynter ME, Cloots R, van Woerkom T, Butnor KJ, Vacek P, Taatjes DJ, Irvin CG, Janssen-Heininger YMW. NF-{kappa}B Activation in Airways Modulates Allergic Inflammation but Not Hyperresponsiveness. J Immunol 2004, 173:7003-7009. 2830271, 15557197.
24. Poynter ME, Irvin CG, Janssen-Heininger YMW. Rapid Activation of Nuclear Factor-{kappa}B in Airway Epithelium in a Murine Model of Allergic Airway Inflammation. Am J Pathol 2002, 160:1325-1334. 1867226, 11943717.
25. Alcorn JF, Rinaldi LM, Jaffe EF, van Loon M, Bates JHT, Janssen-Heininger YMW, Irvin CG. Transforming Growth Factor-beta1 Suppresses Airway Hyperresponsiveness in Allergic Airway Disease. Am J Respir Crit Care Med 2007, 176:974-982. 10.1164/rccm.200702-334OC, 2078678, 17761617.
26. Evans CM, Williams OW, Tuvim MJ, Nigam R, Mixides GP, Blackburn MR, DeMayo FJ, Burns AR, Smith C, Reynolds SD, et al. Mucin Is Produced by Clara Cells in the Proximal Airways of Antigen-Challenged Mice. Am J Respir Cell Mol Biol 2004, 31:382-394. 10.1165/rcmb.2004-0060OC, 15191915.
27. Rasband WS. ImageJ. U. S. National Institutes of Health, Bethesda, Maryland, USA. 1997,
28. Barnes PJ. Efficacy of inhaled corticosteroids in asthma. The Journal of allergy and clinical immunology 1998, 102:531-538. 10.1016/S0091-6749(98)70268-4, 9802359.
29. Kamachi A, Munakata M, Nasuhara Y, Nishimura M, Ohtsuka Y, Amishima M, Takahashi T, Homma Y, Kawakami Y. Enhancement of goblet cell hyperplasia and airway hyperresponsiveness by salbutamol in a rat model of atopic asthma. Thorax 2001, 56:19-24. 10.1136/thorax.56.1.19, 1745918, 11120899.
30. Tamaoki J, Tagaya E, Kawatani K, Nakata J, Endo Y, Nagai A. Airway Mucosal Thickening and Bronchial Hyperresponsiveness Induced by Inhaled {beta}2-Agonist in Mice. Chest 2004, 126:205-212. 10.1378/chest.126.1.205, 15249464.
31. Wagers SS, Haverkamp HC, Bates JHT, Norton RJ, Thompson-Figueroa JA, Sullivan MJ, Irvin CG. Intrinsic and antigen-induced airway hyperresponsiveness are the result of diverse physiological mechanisms. J Appl Physiol 2007, 102:221-230. 10.1152/japplphysiol.01385.2005, 17008432.
32. Allen GB, Pavone LA, DiRocco JD, Bates JHT, Nieman GF. Pulmonary impedance and alveolar instability during injurious ventilation in rats. J Appl Physiol 2005, 99:723-730. 10.1152/japplphysiol.01339.2004, 15831795.
33. Pearce N, Beasley R, Crane J, Burgess C, Jackson R. End of the New Zealand asthma mortality epidemic. The Lancet 1995, 345:41-44.
34. Jones R, Reid L. Beta-agonists and secretory cell number and intracellular glycoproteins in airway epithelium. The effect of isoproterenol and salbutamol. Am J Pathol 1979, 95:407-421. 2042325, 36762.
35. Chapman DG, Berend N, King GG, Salome CM. Increased Airway Closure is a Determinant of Airway Hyperresponsiveness. Eur Respir J 2008,
36. Memorandum: Department of Health and Human Services Public Health Services Food and Drug Administration Center for Drug Evaluation and Research. , http://www.fda.gov/ohrms/dockets/AC/07/briefing/2007-4325b_03_05_Salmeterol%20Adverse%20Event%20Review.pdf
37. Kariyawasam HH, Robinson DS. Airway remodelling in asthma: models and supermodels?. Clinical & Experimental Allergy 2005, 35:117-121.
38. Bateman E, Nelson H, Bousquet J, Kral K, Sutton L, Ortega H, Yancey S. Meta-analysis: effects of adding salmeterol to inhaled corticosteroids on serious asthma-related events. Ann Intern Med 2008, 149:33-42. 18523132.
39. Walters EH, Reid DW, Johns DP, Ward C. Nonpharmacological and pharmacological interventions to prevent or reduce airway remodelling. Eur Respir J 2007, 30:574-588. 10.1183/09031936.00007306, 17766634.
40. Eickelberg O, Roth M, Lorx R, Bruce V, Rudiger J, Johnson M, Block L-H. Ligand-independent Activation of the Glucocorticoid Receptor by beta 2-Adrenergic Receptor Agonists in Primary Human Lung Fibroblasts and Vascular Smooth Muscle Cells. J Biol Chem 1999, 274:1005-1010. 10.1074/jbc.274.2.1005, 9873044.
41. Reader JR, Tepper JS, Schelegle ES, Aldrich MC, Putney LF, Pfeiffer JW, Hyde DM. Pathogenesis of Mucous Cell Metaplasia in a Murine Asthma Model. Am J Pathol 2003, 162:2069-2078. 2216702, 12759261.
42. Nakanishi A, Morita S, Iwashita H, Sagiya Y, Ashida Y, Shirafuji H, Fujisawa Y, Nishimura O, Fujino M. Role of gob-5 in mucus overproduction and airway hyperresponsiveness in asthma. Proceedings of the National Academy of Sciences of the United States of America 2001, 98:5175-5180. 10.1073/pnas.081510898, 33183, 11296262.
43. Cohen L, E X, Tarsi J, Ramkumar T, Horiuchi TK, Cochran R, DeMartino S, Schechtman KB, Hussain I, Holtzman MJ, et al. Epithelial Cell Proliferation Contributes to Airway Remodeling in Severe Asthma. Am J Respir Crit Care Med 2007, 176:138-145. 10.1164/rccm.200607-1062OC, 1994213, 17463414.
44. Singer M, Martin LD, Vargaftig BB, Park J, Gruber AD, Li2 Y, Adler KB. A MARCKS-related peptide blocks mucus hypersecretion in a mouse model of asthma. Nature Medicine 2004, 10:193-196. 10.1038/nm983, 14716307.
45. Agrawal A, Rengarajan S, Adler KB, Ram A, Ghosh B, Fahim M, Dickey BF. Inhibition of mucin secretion with MARCKS-related peptide improves airway obstruction in a mouse model of asthma. J Appl Physiol 2007, 102:399-405. 10.1152/japplphysiol.00630.2006, 16946028.
46. Henderson WRJ, Tang L-O, Chu S-J, Tsao S-M, Chiang GKS, Jones F, Jonas M, Pae C, Wang H, Chi EY. A Role for Cysteinyl Leukotrienes in Airway Remodeling in a Mouse Asthma Model. Am J Respir Crit Care Med 2002, 165:108-116.
47. Nguyen LP, Omoluabi O, Parra S, Frieske JM, Clement C, Ammar-Aouchiche Z, Ho SB, Ehre C, Kesimer M, Knoll BJ, et al. Chronic Exposure to Beta-Blockers Attenuates Inflammation and Mucin Content in a Murine Asthma Model. Am J Respir Cell Mol Biol 2008, 38:256-262. 10.1165/rcmb.2007-0279RC, 2258446, 18096872.